-
- Service Offerings
- Managed Market Analysis
- Education and Training
- Competitive Intelligence
- Expanded Access
- Case Studies
- Comparative Effectiveness Review - Diabetes
- Expanded Access
- Comparative Cost Analysis - Pharmaceuticals
- Healthcare Reform Analysis
- Health Technology Assessment - Oncology
- Reimbursement Call Center and Patient Assistance Program Design - Multiple Product Classes
- Reimbursement Training and Field Reimbursement Call Tracking Tool
- Competitive Intelligence - Urology
- Product Commercialization and Reimbursement Landscape Analysis - Oncology
- Clinical Services Evaluation - Specialty Pharmacy
- Commercialization Strategy - Deep Vein Thrombosis
- Coverage Analysis - Drug Delivery System
- Reimbursement Coverage and Coding Analysis - Vascular Stents
- Health Economic Analysis - Rheumatoid Arthritis
- Health Economics Analysis - Diabetes Mellitus Blood Glucose Monitoring
- Comprehensive Clinical Analysis and Clinical Protocol Design - Migrane
- Outcomes Research Plan - Gastroenterology
- Clinical Compendium and Gap Analysis - Pain Management
- Reimbursement Landscape Analysis - Rare Bleeding Disorders (Hemophilia)
- Disease Area Review and Burden of Illness Analysis - Oncology
- Hospital Inpatient Payor Claims Analysis - Hospital Acquired Infections
- Health Economic Analysis - Orthopedics
- Market Valuation - Opioids
- Meta Analysis - HIV (Human Immunodeficiency Virus)
- AMCP Dossier - Dermatology
- Competitive Intelligence - Infectious Diseases
- Competitive Intelligence - Contraception
- Reimbursement Landscape Analysis - Urology
- Health Economics Analysis - Crohn's Disease
- Comprehensive Reimbursement and Health Economic Analysis - Neurovascular Disease
- Patient Assistance Program Design - Insulin Products
- Health Technology Assessment - Wound Therapy System
Case Studies
Market Valuation - Opioids
Insight
A biotechnology company with a broad product pipeline sold one of its less valuable products to a large, pharmaceutical company. When the sales of that product appeared to spike under new ownership, shareholders raised concerns.
Strategy
The Aequitas Group developed an, evidence-based, fair market valuation of the product’s financial reports. Using publicly available sales and market data to determine key sales projections, The Aequitas Group examined the product’s sales history, market share and market potential information for the approved indications to create a model for immediate use in financial press releases. The Aequitas Group’s results confirmed that the product would likely face serious competition from generics.
Execution
This analysis, conducted in a double-blinded fashion to ensure reliability, demonstrated to the shareholders of the company that sold the product that the decision was sound.
© 2009 The Aequitas Group, Inc. All Rights Reserved.